A Phase 3 interventional study of disodium EDTA and Oral Multi Vitamins/Minerals (OMVM) in Diabetes and Myocardial Infarction, sponsored by Mt. Sinai Medical Center, Miami. Completed at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Mt. Sinai Medical Center, Miami · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,023 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 388 under way, 12 of them phase 3. Diabetes Mellitus · United States.
Among the 3,023 studies in Diabetes Mellitus with a site in United States, this one is the 175th largest by enrollment of the 2,502 interventional ones that give a count, is one of 125 that started in 2016, is one of 306 in phase 3, and was the 1,895th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →289 of the 3,023 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
Wayne State University · Sites in United States
Ages 16–20
Mayo Clinic · Sites in United States
Ages 18+
Montefiore Medical Center · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,023 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 262 · Phase 2 371 · Phase 3 340 · Phase 4 215
First in 1976; this study’s year is marked. 125 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,000 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 82 across the 2,502 interventional studies, 159 across the 499 observational. Of the 2,399 that completed or were terminated, 991 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
852 of 3,023 have an industry lead sponsor. The 10 most frequent:
Mt. Sinai Medical Center, Miami is the lead sponsor of 17 studies on the registry; none are open to participants now.
Mt. Sinai Medical Center, Miami has 2 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
139 of the studies in Diabetes Mellitus with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03982693Phase 3Mt. Sinai Medical Center, MiamiTrial to Assess Chelation Therapy in Critical Limb Ischemia | 2026-12 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT02262832Phase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy | 2027-07-31 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT07556354University of Alabama at BirminghamEmpowering Faith-based Communities to Provide Personalized Diabetes Self-management Education and Support (DSMES) in the Magic City | 2026-11 |
Add all 139 to your calendar (.ics) → With an account.
Among the 3,023 studies in Diabetes Mellitus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Trial to Assess Chelation Therapy 2 (TACT2) is a randomized, double blind controlled factorial clinical trial of edetate disodium-based chelation and high-dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infarction (MI).
The primary objective of TACT2, therefore, is to determine if the chelation-based strategy increases the time to the first occurrence of any of the components of the TACT2 primary endpoint: all-cause mortality, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina compared to the placebo chelation strategy.
TACT2 is a 2x2 factorial trial testing 40-weekly edetate disodium-based chelation infusions and twice daily high-dose oral multivitamins and multiminerals (OMVM) in a placebo-controlled design.
TACT2 is being carried out to replicate the findings of TACT1, which found a striking reduction of recurrent cardiovascular events in post-MI diabetic patients receiving edetate disodium-based chelation therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
History of myocardial infarction based on the Universal Definition of MI.
Exclusion Criteria:
a. Prior intravenous chelation therapy consisting of > 1 infusion within 5 years; if only 1 infusion took place, patient cannot be enrolled for at least 12 months after said infusion.
b. Oral chelation therapy with an approved oral chelating agent within 2 years.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
Drug: disodium EDTA · Dietary Supplement: Oral Multi Vitamins/Minerals (OMVM)
Active disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
Drug: disodium EDTA
Placebo disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
Dietary Supplement: Oral Multi Vitamins/Minerals (OMVM) · Drug: Placebo disodium EDTA
Placebo disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
Drug: Placebo disodium EDTA · Dietary Supplement: Placebo Oral Multi Vitamins/Minerals (OMVM)
IV Disodium Ethylene diamine tetra acetic acid in 500 cc
Also known as: EDTA
6 tablets of Multi-vitamin/Multimineral daily
IV Placebo comparator- 500 normal saline
6 tablets of a placebo Multi-vitamin/Multimineral daily
Primary Composite Outcome
Time to first event: myocardial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or death from any cause
Time frame: 48 month follow-up (median)
Secondary Composite Outcome
Time to first event: myocardial infarction, stroke, or death from cardiovascular causes
Time frame: 48 month follow-up (median)
Secondary Outcome
Time to All-Cause mortality
Time frame: All-Cause Mortality was assessed through study completion, up to 48 months (median)
A total of 1,000 patients were enrolled at 88 clinical centers from United States (83) and Canada (5). The first patient was enrolled on October 18, 2017 and the last patient on December 31, 2020. Each patient was randomly assigned to 1 of the 4 treatment groups.
| Milestone | Active/Active | Active/Placebo | Placebo/ Active | Placebo/Placebo |
|---|---|---|---|---|
| Started | 250 | 249 | 250 | 251 |
| Completed | 175 | 187 | 182 | 176 |
| Not completed | 75 | 62 | 68 | 75 |
| Withdrew: Withdrawal by subject | 12 | 10 | 17 | 21 |
| Withdrew: Death | 46 | 34 | 35 | 43 |
| Withdrew: Lost to follow-up | 17 | 18 | 16 | 11 |
Time to first event: myocardial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or death from any cause
| Participants | Active/Active | Active/Placebo | Placebo/ Active | Placebo/Placebo |
|---|---|---|---|---|
| Primary Composite Outcome | 85 | 89 | 90 | 86 |
Time to first event: myocardial infarction, stroke, or death from cardiovascular causes
| Participants | Active/Active | Active/Placebo | Placebo/ Active | Placebo/Placebo |
|---|---|---|---|---|
| Secondary Composite Outcome | 50 | 40 | 55 | 41 |
Time to All-Cause mortality
| Participants | Active/Active | Active/Placebo | Placebo/ Active | Placebo/Placebo |
|---|---|---|---|---|
| Secondary Outcome | 50 | 36 | 40 | 49 |
Collected over All adverse events were collected from randomization until 30 days after their final infusion, approximately 13 months All-Cause Mortality was assessed through study completion, up to 48 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active EDTA/Active Vitamins | 50/250 (20%) | 41/250 (16.4%) | 0/250 (0%) |
| Active EDTA /Placebo Vitamins | 36/249 (14.5%) | 40/249 (16.1%) | 0/249 (0%) |
| Placebo EDTA/ Active Vitamins | 40/250 (16%) | 40/250 (16%) | 0/250 (0%) |
| Placebo EDTA/Placebo Vitamins | 49/251 (19.5%) | 40/251 (15.9%) | 0/251 (0%) |
| Event | Active EDTA/Active Vitamins | Active EDTA /Placebo Vitamins | Placebo EDTA/ Active Vitamins | Placebo EDTA/Placebo Vitamins |
|---|---|---|---|---|
| Infections and infestationsInfections and infestations | 10/250 | 8/249 | 17/250 | 14/251 |
| Cardiac disordersCardiac disorders | 7/250 | 15/249 | 11/250 | 15/251 |
| Renal and Urinary DisordersRenal and urinary disorders | 6/250 | 3/249 | 2/250 | 3/251 |
| Nervous System DisordersNervous system disorders | 6/250 | 0/249 | 3/250 | 6/251 |
| Gastrointestinal DisordersGastrointestinal disorders | 3/250 | 5/249 | 2/250 | 1/251 |
| Metabolism and nutrition disordersMetabolism and nutrition disorders | 4/250 | 5/249 | 1/250 | 0/251 |
| General disorders and administration site conditionsGeneral disorders | 4/250 | 4/249 | 2/250 | 1/251 |
| Vascular disordersVascular disorders | 2/250 | 2/249 | 1/250 | 4/251 |
| Neoplasms benign, malignant and unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/250 | 3/249 | 2/250 | 1/251 |
| Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 2/250 | 2/249 | 3/250 | 2/251 |
| Age, Continuous(years) | Active/Active | Active/Placebo | Placebo/ Active | Placebo/Placebo | Total |
|---|---|---|---|---|---|
| Median | 66 (59 to 72) | 67 (61 to 72) | 67 (61 to 72) | 67 (61 to 72) | 67 (60 to 72) |
| Sex: Female, Male(Participants) | Active/Active | Active/Placebo | Placebo/ Active | Placebo/Placebo | Total |
|---|---|---|---|---|---|
| Female | 61 | 79 | 75 | 55 | 270 |
| Male | 189 | 170 | 175 | 196 | 730 |
| Ethnicity (NIH/OMB)(Participants) | Active/Active | Active/Placebo | Placebo/ Active | Placebo/Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 46 | 53 | 53 | 46 | 198 |
| Not Hispanic or Latino | 200 | 191 | 197 | 201 | 789 |
| Unknown or Not Reported | 4 | 5 | 0 | 4 | 13 |
| Race (NIH/OMB)(Participants) | Active/Active | Active/Placebo | Placebo/ Active | Placebo/Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 3 | 1 | 5 |
| Asian | 15 | 11 | 12 | 16 | 54 |
| Native Hawaiian or Other Pacific Islander | 5 | 3 | 5 | 5 | 18 |
| Black or African American | 34 | 22 | 19 | 26 | 101 |
| White | 186 | 194 | 204 | 194 | 778 |
| More than one race | 1 | 3 | 1 | 1 | 6 |
| Unknown or Not Reported | 9 | 15 | 6 | 8 | 38 |
| Region of Enrollment(participants) | Active/Active | Active/Placebo | Placebo/ Active | Placebo/Placebo | Total |
|---|---|---|---|---|---|
| North America | 250 | 249 | 250 | 251 | 1000 |
| Type II Diabetes(Participants) | Active/Active | Active/Placebo | Placebo/ Active | Placebo/Placebo | Total |
|---|---|---|---|---|---|
| Count of participants | 239 | 242 | 235 | 244 | 960 |
| Time from diabetes diagnosis to randomization(years) | Active/Active | Active/Placebo | Placebo/ Active | Placebo/Placebo | Total |
|---|---|---|---|---|---|
| Median | 13 (7 to 20) | 15 (8 to 21) | 15 (7 to 24) | 14 (7 to 21) | 14 (7 to 22) |
| Time from qualifying MI to randomization(years) | Active/Active | Active/Placebo | Placebo/ Active | Placebo/Placebo | Total |
|---|---|---|---|---|---|
| Median | 5 (2 to 9) | 5 (2 to 10) | 5 (2 to 11) | 5 (2 to 10) | 5 (2 to 10) |
10 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2016 to primary completion in Jun 2023, 80 months.
Results were first posted in Oct 2024, 1 year 3 months after primary completion.
Of 63 non-industry phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 79. This study's 80 months is above that.
Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Edetic Acid
Mt. Sinai Medical Center, Miami